Kate Hyde

Kate Hyde, PhD, is an Associate Professor in the Department of Biochemistry and Molecular Biology at the University of Nebraska Medical Center (UNMC) College of Medicine. She also serves as Associate Director for Shared Resources at the Fred & Pamela Buffett Cancer Center. Her laboratory investigates molecular mechanisms of acute myeloid leukemia (AML), with emphasis on chromosome 16 inversion (Inv(16))-driven AML and the oncogenic fusion protein CBFβ-SMMHC.

Education includes:

• Bachelors of Arts in Biology from Washington University in St. Louis
• PhD in Cellular and Molecular Biology from University of Wisconsin-Madison
• Post-doctoral fellowship at National Human Genome Research Institute, NIH

Her research integrates:

• Leukemia and normal blood development pathways
• Regulation of gene expression in hematological malignancies
• Development of targeted therapies using mouse models and drug delivery systems

She collaborates extensively, including projects with UNMC College of Pharmacy on polymeric CXCR4 inhibitors.

Recent publication trends (15 most recent) focus on:

• Leukemia stem cell persistence mechanisms in bone marrow
• CXCR4-targeted drug delivery systems
• Epigenetic regulators (HDAC1) and metabolic dependencies in AML
• Novel therapeutics like liposomal miR-497-5p/venetoclax combinations
• RUNX1/CBFβ-SMMHC transcriptional networks

Dr. Hyde actively mentors students interested in leukemia research and encourages inquiries about lab opportunities.